Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2008 1
2009 1
2010 1
2011 4
2012 3
2013 4
2014 5
2015 4
2016 7
2017 8
2018 11
2019 12
2020 17
2021 17
2022 16
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 38164592

101 results

Results by year

Filters applied: . Clear all
Page 1
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.
Al Mansour L, De Mestier L, Haissaguerre M, Afchain P, Hadoux J, Lecomte T, Morland D, Cottereau AS, De Rycke O, Tlili G, Tordo J, Janier M, Deville A, Walter T. Al Mansour L, et al. J Nucl Med. 2024 Feb 1;65(2):258-263. doi: 10.2967/jnumed.123.266063. J Nucl Med. 2024. PMID: 38212066
Long-term Nephrotoxicity after PRRT: Myth or Reality.
Baum RP, Fan X, Jakobsson V, Yu F, Schuchardt C, Chen X, Zhang J. Baum RP, et al. Theranostics. 2024 Jan 1;14(2):451-459. doi: 10.7150/thno.92487. eCollection 2024. Theranostics. 2024. PMID: 38169589 Free PMC article.
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, Danieli R, Deleporte A, Picchia S, Stathopoulos K, Jungels C, Vanderlinden B, Paesmans M, Ameye L, Critchi G, Taraji-Schiltz L, Velghe C, Wimana Z, Bali M, Hendlisz A, Flamen P, Karfis I. Mileva M, et al. J Nucl Med. 2024 Feb 1;65(2):236-244. doi: 10.2967/jnumed.123.265987. J Nucl Med. 2024. PMID: 38164576 Clinical Trial.
101 results